DexCom, Inc.
DexCom, Inc. (DXCM) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for DexCom, Inc. (DXCM), covering cash flow, earnings, and balance sheets.
DexCom, Inc. (DXCM) Income Statement & Financial Overview
View the income breakdown for DexCom, Inc. DXCM across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $1.04B | $1.11B | $994.20M | $1.004B |
| Cost of Revenue | $447.00M | $459.50M | $400.40M | $377.60M |
| Gross Profit | $589.00M | $654.00M | $593.80M | $626.70M |
| Gross Profit Ratio | $0.57 | $0.59 | $0.60 | $0.62 |
| R&D Expenses | $145.20M | $139.50M | $135.40M | $136.00M |
| SG&A Expenses | $310.10M | $327.40M | $306.40M | $332.70M |
| Operating Expenses | $455.30M | $465.10M | $441.80M | $468.70M |
| Total Costs & Expenses | $902.30M | $924.60M | $842.20M | $846.30M |
| Interest Income | $0.00 | $29.70M | $32.00M | $36.20M |
| Interest Expense | $0.00 | $4.90M | $4.70M | $4.80M |
| Depreciation & Amortization | $60.00M | $57.80M | $55.30M | $52.10M |
| EBITDA | $219.00M | $274.00M | $237.40M | $244.70M |
| EBITDA Ratio | $0.21 | $0.25 | $0.24 | $0.24 |
| Operating Income | $133.70M | $188.90M | $152.00M | $158.00M |
| Operating Income Ratio | $0.13 | $0.17 | $0.15 | $0.16 |
| Other Income/Expenses (Net) | $20.60M | $22.40M | $25.40M | $29.80M |
| Income Before Tax | $154.30M | $211.30M | $177.40M | $187.80M |
| Income Before Tax Ratio | $0.15 | $0.19 | $0.18 | $0.19 |
| Income Tax Expense | $48.90M | $59.60M | $42.80M | $44.30M |
| Net Income | $105.40M | $151.70M | $134.60M | $143.50M |
| Net Income Ratio | $0.10 | $0.14 | $0.14 | $0.14 |
| EPS | $0.27 | $0.39 | $0.35 | $0.36 |
| Diluted EPS | $0.27 | $0.38 | $0.34 | $0.35 |
| Weighted Avg Shares Outstanding | $391.10M | $399.33M | $394.20M | $399.20M |
| Weighted Avg Shares Outstanding (Diluted) | $407.50M | $406.70M | $410.20M | $416.80M |
Financial performance has remained strong, with revenue growing from $1.004B in Q2 2024 to $1.04B in Q1 2025. Gross profit continued to perform well, with margins at 57% in the latest quarter. Operating income reached $133.70M in Q1 2025, holding a steady 13% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $219.00M. Net income dropped to $105.40M, keeping EPS at $0.27. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan